前收市價 | 3.1700 |
開市 | 3.0000 |
買盤 | 2.3000 |
賣出價 | 2.9000 |
拍板 | 92.50 |
到期日 | 2024-05-17 |
今日波幅 | 2.3300 - 3.2000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 79 |
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.